Omeros (NASDAQ:OMER) Trading 9.2% Higher – Time to Buy?

Omeros Co. (NASDAQ:OMER)’s share price was up 9.2% during trading on Wednesday . The stock traded as high as $8.74 and last traded at $8.64. Approximately 291,193 shares traded hands during trading, a decline of 47% from the average daily volume of 544,800 shares. The stock had previously closed at $7.91.

Analyst Ratings Changes

Several research analysts recently issued reports on OMER shares. StockNews.com upgraded shares of Omeros from a “sell” rating to a “hold” rating in a research note on Tuesday. D. Boral Capital restated a “buy” rating and set a $36.00 price target on shares of Omeros in a report on Tuesday. Finally, Needham & Company LLC reiterated a “hold” rating on shares of Omeros in a research note on Tuesday. Three analysts have rated the stock with a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Omeros presently has a consensus rating of “Moderate Buy” and an average price target of $22.50.

Omeros Stock Up 5.7 %

The stock has a market capitalization of $484.46 million, a P/E ratio of -3.62 and a beta of 2.03. The business has a fifty day moving average price of $8.64 and a 200-day moving average price of $7.61.

Institutional Trading of Omeros

A number of large investors have recently made changes to their positions in the stock. Truvestments Capital LLC increased its position in shares of Omeros by 116.5% during the 4th quarter. Truvestments Capital LLC now owns 3,102 shares of the biopharmaceutical company’s stock valued at $31,000 after purchasing an additional 1,669 shares during the last quarter. Tower Research Capital LLC TRC lifted its position in shares of Omeros by 79.0% in the fourth quarter. Tower Research Capital LLC TRC now owns 4,467 shares of the biopharmaceutical company’s stock valued at $44,000 after acquiring an additional 1,972 shares in the last quarter. Quantbot Technologies LP bought a new position in shares of Omeros in the fourth quarter worth about $46,000. BNP Paribas Financial Markets grew its position in shares of Omeros by 130.6% during the third quarter. BNP Paribas Financial Markets now owns 12,388 shares of the biopharmaceutical company’s stock worth $49,000 after purchasing an additional 7,016 shares in the last quarter. Finally, Picton Mahoney Asset Management raised its stake in Omeros by 692.5% during the 4th quarter. Picton Mahoney Asset Management now owns 5,040 shares of the biopharmaceutical company’s stock valued at $50,000 after purchasing an additional 4,404 shares during the period. 48.79% of the stock is currently owned by institutional investors.

About Omeros

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company’s products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.